• Cape Town As Nelson Mandela wisely said: "A good head and a good heart are always a formidable combination."  IP specialists and creators are among the brightest people in commerce, and we all know innovation is the key to international development.  With this spirit, the South African Department of Science and Technology and its co-sponsors encourage you to attend a conference on "Accelerating Intellectual Property and Innovation in South Africa," to be held on September 18-20, 2011 in Cape Town, at the Cape Sun Hotel.  This conference is an opportunity for patent and innovation specialists internationally to share best practices with their peers in South Africa, in a forum designed to create networking and future business opportunities with the goal to expand South Africa's growing domestic capability.

    South Africa Flag This conference also provides the opportunity to celebrate a huge accomplishment by South Africa, which recently became the first developing country in the world to pass transformational legislation allowing publicly funded universities and scientific research councils to own the IP they generate and to commercialize it for the benefit of the country and the world.  The newly promulgated "Intellectual Property Rights from Publicly Financed Research and Development Act" (51 of 2008) also establishes a new office to administer the legislation, the National IP Management Office ("NIPMO").  The U.S. Bayh Dole Act fundamentally changed the landscape of the biotechnology industry in the U.S.  South Africa has now designed its own unique path to create and grow innovator companies, becoming an inspiring model for other developing countries.

    South African Department of Science and Technology The lead sponsor of the event is the South African Department of Science and Technology.  The Co-Organizing Chairs of the event are Sherry Knowles, Knowles Intellectual Property Strategies, Atlanta GA (former Chief Patent Counsel, GlaxoSmithKline) and McLean Sibanda, Chief Executive Officer, The Innovation Hub, Pretoria ZA (instrumental in drafting and facilitating the new IPR legislation).

    Key speakers currently include:

    • Chief Judge Randall Rader of the U.S. Court of Appeals for the Federal Circuit
    • Judge Brian Southwood, Gauteng High Court, Pretoria South Africa
    • Teresa Rea, Deputy Commissioner of the U.S. Patent & Trademark Office
    • Phil Mjwara, Director General of Department of Science and Technology of South Africa
    • Todd Dickinson, Executive Director of the AIPLA
    • The impending Chief Director, National IP Management Office of South Africa
    • James Pooley, Deputy Director General for Innovation and Technology, World Intellectual Property Organization
    • John Whealan, Associate Dean for IP, George Washington Law School
    • Roy F. Waldron, Chief IP Counsel, Pfizer Corp.
    • Professor Tana Pistorious, University of South Africa, Professor of Mercantile Law
    • Guobin Cui, Associate Professor, Tsinghua University, School of Law, Beijing, China
    • Anthony E. Lockett, M.D., Medical Director and Regulatory Consultant, Information Change Ltd.
    • McLean Sibanda, CEO The Innovation Hub, Pretoria ZA
    • Sherry Knowles. Knowles Intellectual Property Strategies

    The panel on entrepreneurial approaches to IP creation will include Professor Dennis C. Liotta, the Samuel Chandler Dobbs Professor of Chemistry at Emory University, co-inventor of HIV drug Emtricitabine which is a key component of Gilead's HIV drugs Truvada and Atripla, and co-founder of iThemba Pharmaceuticals, a drug discovery company in South Africa focused on developing drugs for neglected tropical diseases; and Dr. Frank Litvack, a prominent interventional cardiologist, former Co-Director of the Interventional Cardiology Center at Cedars Sinai Medical Center in Los Angeles, Professor of Cardiology at UCLA School of Medicine, and successful serial entrepreneur of medical device and pharmaceutical companies.

    A Welcome Reception will be held Sunday evening, September 18.  The conference dinner Tuesday September 20 will serve as the formal introduction of South Africa's new legislation and implementing agency by the Department of Science and Technology.  It will also give participants and attendees the opportunity to commend the country for this impressive step to expand a domestic innovator industry which is capable of contributing to African and global advancement.

    The Agenda currently includes the following panels over two days: 

    Panel 1 — The Role of the Judiciary and the Court System in Shaping IP Policy

    Panel 2 — Private Ownership of Federally Funded Research:  Strategy, Implementation, Goals and Challenges in Developing Countries

    Panel 3 — IP Education and Capacity Development for Intellectual Property and Innovation in Developing Countries   

    Panel 4 — Creating a Model Patent Office for Developing Countries

    Panel 5 — Entrepreneurial Approaches to Creating IP and Innovation — Adapting Approaches for Developing Countries

    Panel 6 — Accelerating Commercialization and Attracting Foreign Direct Investment

    Panel 7 — Regulatory Aspects of Product Development and Commercialization — Data Exclusivity and Acceleration of Drug and Device Approvals in Developing Countries

    The website for registration will open May 2, 2011.  Please contact JudyLane Consulting (London), the conference organizers, with any inquiries (annie@judylaneconsulting.com or dawn@judylaneconsulting.com) or Ms. Nomkhosi Madwe, Director: Operations and Special Projects: National Intellectual Property Management Office, Department of Science and Technology, South Africa (Nomkhosi.madwe@dst.gov.za).

  • Chicago #5 Patent Resources Group (PRG) and Management Forum will be offering two one-day courses on the European Patent system on June 2-3, 2011 at the McDonnell Boehnen Hulbert & Berghoff LLP conference center in Chicago, IL.

    The June 2 course, entitled "EPO Opposition & Appeals — The Case Law," will cover the following topics:

    • Introduction to oppositions
    • Filing and admissibility of oppositions
    • Substantive examination of oppositions
    • Introduction to Appeals
    • Filing, Admissibility and Examination of Appeals
    • Evidence
    • Petitions for Review
    • Oral Proceedings

    The June 3 course, entitled "European Patents — The Case Law," will the following topics:

    • Industrial Application
    • State of the Art
    • Novelty
    • Inventive step
    • Sufficiency, Clarity, Amendments
    • Exclusions from Patentability
    • Exceptions to Patentability

    PRG Additional information regarding each course can be found here (June 2) and here (June 3).  A brochure for the courses, including an agenda and registration form can be downloaded here.  The registration fee for each course is $995 (or $1,795 for both courses).  Those interested in registering for the event, can do so here.

  • Brochure The Intellectual Property Owners Association (IPO) will be holding its 6th International Judges Conference on Intellectual Property Law on May 23-25, 2011 in Brussels, Belgium.  The conference will provide discussions on the following topics:

    • Keynote Address — Hon. Randall R. Rader, Chief Judge for the U.S. Court of Appeals for the Federal Circuit;

    • Remedies and Damages — Judge Toshiaki Iimura, IP High Court, Japan; Judge Seong-soo Park, Suwon District Court, Korea; Judge Robert Van Peursem, Rechtbank's–Gravenhage, The Hague, Netherlands; and Judge T. John Ward, U.S. District Court for the Eastern District of Texas;

    • Obviousness and the Role of Secondary Considerations in Deciding Obviousness — Judge Klaus Grabinski, Federal Supreme Court, Germany; Gerhard Hermann, Vossius & Partner, Germany; Eiji Katayama, Abe, Ikubo & Katayama, Japan; Judge Kathleen O'Malley, U.S. Court of Appeals for the Federal Circuit; George Pappas, Covington & Burling LLP, United States; and Judge Shuhei Shiotsuki, IP High Court, Japan;

    • Patentable Subject Matter — Judge Robin Jacob, Royal Courts of Justice, United Kingdom (retired); J. Michael Jakes, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, United States; Judge David Kitchin, Royal Courts of Justice, United Kingdom; S. Sam Li, Jincheng Tongda & Neal Law Firm, People's Republic of China; Judge Peter Meier-Beck, German Federal Supreme Court, Germany; Judge Pauline Newman, U.S. Court of Appeals for the Federal Circuit; Jochen Pagenberg, Bardehle Pagenberg, Germany; and Judge Luo Xiao, Supreme People's Court, People's Republic of China;

    • Swiss Federal Patent Court — Judge Dieter Brändle, Handelsgericht Des Kantons Zurich, Switzerland;

    • Keynote Address — Director David Kappos, U.S. Patent and Trademark Office;

    • Discovery and Privilege — Judge Christopher Floyd, Patents Court, United Kingdom; Judge Els Herrogodts, Court of Appeal, Belgium; Judge Madame Marie-Claude Hervé, Tribunal De Grande Instance De Paris, France (invited); and Judge Kent A. Jordan, U.S. Court of Appeals for the Third Circuit;

    • Patent Reform — Judge Zhipei Jiang, Professor of Law, Chief Justice of IPR Tribunal, Supreme People's Court of the People's Republic of China (Retired); Alastair Payne, Matheson Ormsby Prentice, Ireland; and Herbert C. Wamsley, Intellectual Property Owners Association, United States.

    A complete brochure for the meeting, including an agenda, list of speakers, and registration form can be downloaded here.  The registration fee for the conference is $1,475.  Those interested in registering for the meeting can do so here.

  •     By Donald Zuhn

    Launch of Prioritized (Track 1) Examination Postponed

    USPTO Seal Earlier this month, the U.S. Patent and Trademark Office announced that it would begin accepting requests for prioritized examination of patent applications (i.e., the Track 1 portion of the Enhanced Examination Timing Control Initiative outlined in a Federal Register notice in June 2010) on May 4, 2011 (see "USPTO to Launch Prioritized Examination on May 4th").  Today, Hal Wegner reported in his e-mail newsletter that USPTO Director David Kappos sent a message to USPTO employees this afternoon, notifying them that "[t]he Track One expedited patent examination program, scheduled to go into effect on May 4, 2011, is postponed until further notice."  According to Mr. Wegner's e-mail, "[t]he cancellation is due to budgetary cuts; whether and when prioritized examination may be reinstated is unclear."


    USPTO and UKIPO Make Progress on Joint Action Plan

    UKIPO On April 5, the U.S. Patent and Trademark Office announced that the U.S. and United Kingdom had made progress on a joint action plan launched in March 2010 "to combat the problem of patent backlogs and their effects on the economy and job creation."  The joint action plan is based in part on a study commissioned by the UK Intellectual Property Office (UKIPO), entitled "Economic Study on Patent Backlogs and a System of Mutual Recognition," which examined the economic impact of delays in processing patents, and which found that patent office delays stifle innovative competitiveness, drag down R&D investments, and minimize incentives to create, especially for inventions in the hi-tech sectors.  According to the USPTO press release, the joint action plan "allow[s] a patent examiner in one office to reuse work done by an examiner in the other office on a corresponding application to the maximum extent possible in order to reduce duplication of work, speed up processing and improve quality in both offices."  The plan has thus far resulted in IT system enhancements that have provided USPTO and UKIPO examiners with better electronic access to search and examination reports prepared in each office and the development of resource manuals and instruction handbooks to enhance common understanding of practice in each office.


    March 2, 2011 Declared "Federal Holiday"

    USPTO Building Facade In a notice issued on March 30, the U.S. Patent and Trademark Office indicated that its customer service window in the Randolph Building in Alexandria, VA was unexpectedly closed at 11:00 pm on March 2, 2011 due to a power outage.  In light of the window's closing, the Office announced that it "will consider Wednesday, March 2, 2011, to be a 'Federal holiday within the District of Columbia' under 35 U.S.C. § 21 and 37 C.F.R. §§ 1.6, 1.7, 1.9, 2.2(d), 2.195 and 2.196."  As a result, "[a]ny action or fee due on Wednesday, March 2, 2011, will be considered as timely for the purposes of, e.g., 15 U.S.C. §§ 1051(b), 1058, 1059, 1062(h), 1063, 1064, and 1126(d), or 35 U.S.C. §§ 119, 120, 133 and 151, if the action was taken, or the fee paid, on the next succeeding business day on which the USPTO was open, that is, Thursday, March 3, 2011 (37 C.F.R. $5 1.7(a) and 2.196)."  Good news for anyone who may have missed a March 2, 2011 deadline by a day.

  • Dear fellow patent attorney:

    Boundy, David I need your immediate assistance to help defeat a particularly bad patent bill now in its final stages of consideration by the U.S. Congress.  Congress may well be on the verge of passing a great threat to our patent system.  You have seen the blogs and emails explaining how the America Invents Act (formerly the Patent Reform Act of 2011) will dismantle our carefully-balanced patent system, the system that has made America the innovation engine for the world.  Other countries innovate at half our rate.  The multinationals want to "harmonize" our laws with those unsuccessful systems for their own convenience.  This bill imposes about $1 billion in costs by taking away options that domestic American businesses use, to save a comparatively trivial amount for the Patent Office and a small number of multinational corporations.

    The appendix to this letter outlines the proposed law and how it will significantly damage our clients, our profession, and our country.

    Because this bill has passed the full Senate and the House Judiciary Committee, it could be enacted within weeks.  The big multinational corporations have plowed untold sums of money into lobbying, and have the bill they want.  It's essential that Congress hear from domestic American businesses and inventors, and hear from them now.  Congress desperately needs to learn from small businesses and startups how they actually use the patent system to create new products, jobs, and wealth.

    Congress is on recess during the next two weeks, April 18 to May 2, and your Representative will be in your district.  This period is your best opportunity to inform your Representative that this bill will destroy American jobs by making it impossible for startups, small companies, and university spinoffs to protect the inventions they create, to obtain the funding they need to commercialize their inventions, and to earn the profits they need to grow new R&D-intensive businesses.

    The "Asks"

    Go to www.house.gov to find your Representative's contact info.  To schedule a meeting, many offices will want you to FAX in a request letter.  Second best is a phone call to your district office (not the D.C. office).  Third best — and far less effective, but better than nothing — is an email.  www.reformaia.org can help you with some of these contacts.

    Ask your clients to join you at a meeting, or at a minimum, to call or write.  This letter is accompanied by a "script" you can give to clients for them to make their calls.

    • Your representatives should support an amendment to strike the "first-inventor-to-file" section.  This section removes any practical grace period, and will destroy future jobs:  Also, it is likely unconstitutional, and the legal uncertainty will be unacceptable to businesses.

    • If the "first-inventor-to-file" provision is not struck, urge your representative to vote against the entire bill, regardless of any other changes that might be incorporated.

    If you live in Ohio, call Governor Kasich's office, (614) 466-3555.  Point out that the governor's $700 million Ohio Third Frontier jobs program cannot work, and that the Innovation Ohio Loan Fund will be not be repaid, if the federal Patent Act is changed to deter investment in university spin-offs and startups, and to make it harder for new businesses to succeed.

    Please take the opportunity to meet or phone, or at least email your Representative.  (A phone call has several times the weight of an email, and a meeting will have many times the impact of a phone call).  You will be more likely to get a personal meeting, and you will have far more impact, if you as an attorney bring one or two of your clients with you.  Stay away from patent jargon, because the person you talk to will almost certainly know nothing about patent law.  It's crucial that you discuss the effects of the bill in terms of destruction of innovation, jobs, start-up businesses, and the like, issues that a Representative or staffer can relate to.  Urge your clients to join you for a meeting.

    It's crucial to act now.  Please help preserve our gold standard patent system, one of the biggest engines of job growth in the U.S., and part of the reason U.S. attorneys can create so much more value for their clients than other attorneys.

    David Boundy
    Boston MA
    (212) 294 7848, e-mail: PatentProcedure at gmail dot com

    How the America Invents Act Changes Patent Law

    The bill tilts the playing field in favor of multinational corporations and market incumbents.  The bill shifts from today's emphasis on disclosure and disruptive innovation to favor trade secret and market incumbency, in the following ways:

    • The § 102(a) grace period is totally repealed.  Every inventor will be in a race against all other possible disclosures — no inventor will have the time to perfect and test an invention before filing.  All companies will be forced to file before an invention is fully understood or tested.  That will be expense for your clients and trouble for you as an attorney, and reduce patent quality.

    • Inventors, entrepreneurs, and startups use the grace period of § 102(a) to meet with investors, do the trial-and-error of R&D, and test their inventions.  Under today's law, the implied obligations of confidentiality in conversations with investors and early-stage partners give sufficient protection to permit these ordinary business activities.  The bill repeals all these protections, and replaces them with a flimsy grace period that creates unacceptable risk of loss of patent rights, that no business can rely on — though adds strong protections for large companies that can raise all their financing, and do all their manufacturing and testing in-house.  Inventors won't be able to talk to investors without a patent, and won't be able to file an application without an investor.

    • The bill states that an inventor can recover patent rights if he can prove that all other disclosures originated with the inventor — but the bill neglects to create a procedural forum for showing derivation in cases where the leak is not embodied in a patent application, or where the leak neglects to attribute the original inventor.  As a practical business matter, the bill leaves no commercially-feasible grace period, an integral part of U.S. patent law since 1839 — you will have to file every application as soon as possible, often long before the invention is ready.

    • The bill provides that all disclosures within and by a single company do not create bars.  This is great for multinational companies, with large in-house staffs, but totally useless for a startup or small company that has to partner with outsiders.  Startups use and need the options and protections of current law, but the new bill cuts them away.

    • A single offer for sale or public demonstration one day before filing a patent application will irretrievably destroy patent rights, if the poorly-drafted language is interpreted literally.

    • The § 102(b) grace period is cut back — it no longer protects against activities by third parties, but only the inventor's own activities.

    • As a patent attorney, you will no longer have time to do a good job preparing a patent application, you'll be "forced to file" prematurely.  This will expose you to risks and destroy your weekends.  Poor initial applications will drive up post-filing prosecution costs.  You will find yourself as the blocking point for many of your clients' business activities, harming your client relationships.

    The bill also destroys commercial certainty and corrupts the incentives in the system:

    • Various statutory requirements that an applicant act "without deceptive intention" are repealed — in the future, applicants will have incentive to act with deceptive intent.

    • Key terms of art are redefined — you've spent a career learning the meaning of "on sale" and "public use," but the legislative history fundamentally redefines these terms.  It will take decades for courts to establish new precedent to provide any meaningful commercial certainty.

    • The Metallizing Engineering "secret commercial use" bar is repealed — a company will be able to use an invention as a trade secret, and then spring a patent on the public years later.  That favors market incumbents, but makes innovation harder for everyone else.

    • The "best mode" requirement is reduced to a sham:  a patentee will be permitted to disclose only a fictitious embodiment, while holding the best as a trade secret.

    • The bill gives companies the right to patent and repatent inventions for years, to keep them locked up, neither using them nor permitting them to be used, for far longer than 20 years.

    • Several aspects of the "first-inventor-to-file" provision — the ones that give patents to second inventors, and to companies that kept inventions in secret for years before filing patent applications — violate constitutional limits on Congress' authority — years more litigation and commercial uncertainty.

    • The Act allows Wall Street banks to attack "business method" patents that they are infringing.  This doesn't extend to any other industry, only business methods — another Wall Street giveaway.

    The bill is out of committee — further amendments are unlikely.  It is literally impossible to alter the bill to meet the needs of startups through an amendment strategy at this late date.  The multinationals and their congressional allies smell victory.  They see no reason to allow any weakening of their preferred bill through amendments favoring small businesses.  The only option at this point is to vote it down.


    Typical inventor activities that no longer "work"

    Most startups, and many inventions at established companies, go through at least one of two "stories."  They're reasonable commercial practice under today's law, but not under the bill:

    • An entrepreneur with nothing but an idea typically has to present his idea to dozens of venture capitalists and potential manufacturing or marketing partners, without formal confidentiality agreements, to get a company started.  (VC's never sign confidentiality agreements for first meetings.)  This works under today's law, because of the implied obligation of confidentiality and the protection of § 102(a), but under the bill, these conversations will create commercially-unacceptable risks to the investor and partner.  U.S. inventors will be under the same "Catch-22" as European inventors — unable to talk to potential investors until a patent application is filed, but unable to file a patent application without an investor.  Startups will die before being born.

    • Companies that need a long "invention incubation" period — trial and error, conceive, test and discard, until finding the "magic combination" of techniques — use the § 102(a) grace period to do their R&D in confidence, and file patent applications only when it's clear which inventions are valuable, and how they work.  Under the bill, a company will have to file a continuous stream of patent applications, many directed to inventions that are dumped under current law.  This will increase patent costs remarkably.

    Almost every startup goes through one of these two, many through both, as new companies create new wealth and new jobs under today's law.  Inventors wait to file quality patent applications until they have quality inventions.  America's unique and strong right to file in the future, after the inventor and investor know whether the invention is valuable, makes business easy, and prevents wasted costs for inventions that prove worthless.

    The "America Invents Act" revokes this historic right.  Property rights turn on non-business legal technicalities created to satisfy bureaucrats, technicalities that will cost $1 billion annually.  The bill requires a company to file premature, hasty, and expensive patent applications on every baby-step idea to preserve rights against third parties who are dabbling in the field without intent to develop a commercial product.  The America Invents Act makes these two stories nonviable for startups — because the authors "didn't think" about them, or didn't want to.

    In 2010, the Kauffman Foundation and Census Bureau released two studies on job creation.  Both found that "net job growth occurs in the U.S. economy only through start up firms."  If creating new jobs is Congress's Job One, then killing the America Invents Act is a good place to start.

    The proponents' arguments do not survive scrutiny

    Proponents suggest that the bill does away with complex and costly interferences.  That's true, but irrelevant.  Under 100 applications per year end up in interferences.  In contrast, the change to today's "§ 102(a)" grace period affects commercial decisions and raises costs for hundreds of thousands of inventions per year, during the time before filing, by giving inventors and patent attorneys time to get it right the first time.  Because the Patent Office has no insight into the pre-filing process of invention, it simply hasn't taken into account the realities of invention incubation and the costs of its proposal.  Further, the proposed replacement, "derivation proceedings," are the most costly disputes in patent law.

    Second, proponents argue that provisional applications will be a cheap way to preserve rights.  But that isn't true under the new law.  Under current law, a cheap provisional is useful to show conception and diligence.  But under Patent Reform, a provisional application only provides legal benefit if prepared with full § 112 ¶ 1 care and completeness.  For a typical startup invention, the cost in attorney fees and inventor time for a provisional application is $10,000 or more — a formidable barrier to an entrepreneur's first conversation with an investor.

    Third, proponents argue, "The bill locks in rights if you publish a disclosure of the invention."  But all companies rely on secrecy for their future plans.  No company publishes its most sensitive and advanced technology years before introduction.  This argument ignores business reality.

  • By Kevin E. Noonan

    Wall Street Journal The anti-patent virus seems to have moved across town in Manhattan, from the 8th Avenue editorial offices of The New York Times to 6th Avenue, from the aristocratic edifice ruled by the Sulzberger family to the business environs of the hardscrabble upstart Aussie, Rupert Murdoch at The Wall Street Journal.  The theme (and even some of the rhetoric) are the same, but instead of an erudite academic, we have Peter Huber (below), senior partner of Kellogg, Huber, Hansen, Todd, Evans & Figel and fellow of the Manhattan Institute, giving us his views on what is wrong with the U.S. patent system.

    Huber, Peter The piece, entitled "Digital Innovators vs. Patent Trolls" and published on Monday, concerns the Supreme Court's consideration of the Microsoft v. i4i appeal, and as has been done elsewhere, attempts to create a dichotomy between productive, innovative companies and non-practicing entities, using the pejorative term "patent troll" to describe them.  The dichotomy is false as a general rule (although there are certainly NPEs that aggregate patents from failed companies and assert them; what the piece does not address is the reluctance of some established companies to honor patent rights and license innovation rather than expropriating it, and the extent to which this behavior contributes to the difficulties that cause innovative companies to fail).

    Mr. Huber finds significance in the Supreme Court's interest over the past ten years in patent law, after a hiatus that permitted the Court of Appeals for the Federal Circuit (created by Congress to harmonize U.S. patent law) to get its institutional legs under it.  What is unmentioned and perhaps forgotten is the motivation for the creation of the Federal Circuit:  the difficulties U.S. inventors and companies had at a time when foreign competition was threatening the U.S. economy and preeminence in the world.  While one of the two cases Mr. Huber mentions (KSR Int'l Co. v. Teleflex Inc.) involved a perception (created by the lawyers who crafted the certiorari petition) that patents on "obvious" inventions were being improvidently granted, most of the cases under Supreme Court review have involved harmonizing Federal Circuit precedent with other regional courts of appeal on standards for declaratory judgment actions (MedImmune, Inc. v. Genentech, Inc.) and injunctions (eBay Inc. v. MercExchange, L.L.C.), as well as the scope of the appellate court's supervisory role over the U.S. Patent and Trademark Office (Dickenson v. Zurko), and in patent matters having little to do with patent quality, such as the extraterritorial extent of U.S. patents (Microsoft Corp. v. AT&T Corp.), patent exhaustion (Quanta Computer, Inc. v. LG Electronics, Inc.) and how far the statutory safe harbor for preclinical activities protect potential infringers (Merck KGaA v. Integra Lifesciences I, Inc.).  Indeed, two cases most clearly exemplifying the differences between the Supreme Court and the Federal Circuit (Warner-Jenkinson Co. v. Hilton Davis Chemical Co. and Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.) had to do with the doctrine of equivalents, which actually extends the scope of the patent right beyond the literal meaning of the claims and in which, surprise!, the Supreme Court reversed efforts by the Federal Circuit to limit application of the doctrine in favor of narrower patents.

    So while there is the perception that "poor quality" patents are being granted, fueled in large part by big companies who would rather not be bothered respecting the patent rights of small ones, Supreme Court decisions are not the cause of it.  Indeed (although Mr. Huber could not have anticipated it), the Supreme Court appeared unimpressed by the idea, advanced by Microsoft, that lay juries should be permitted to overrule the considered opinion of the Patent Office using a preponderance of the evidence standard for invalidity.  Although the Court seemed more receptive to the idea in cases where the Office did not consider the art, the Justices also seemed less concerned than Microsoft that juries could understand that the quantum of evidence needed to constitute "clear and convincing" evidence could be less for invalidity arguments based on such unconsidered art.

    In places Mr. Huber sings from the same hymnbook used across town at the Times, that examiners are overwhelmed and cannot properly do their jobs, and that it is only in the fire of litigation that the validity of patents can be properly assessed.  The force of this argument is blunted, however, by the fact that "only 2% of patents end up in court," and while some of this is due to licensing and settlement rather than litigation, the statistic certainly implies that patents are not clogging court calendars.  Mr. Huber seems to think that patent examiners are less skeptical of patentability than judges or juries; in reality, examiners in the Office operate under no presumption of validity, and construe claims as broadly as they can reasonably be construed, which tends to expand the scope of relevant prior art and make it less likely that a patent will be granted.

    Ironically, in view of recent charges of ad homimen argument raised by a suggestion that actual experience could be useful in making and assessing arguments about patent quality, Mr. Huber's article advances the argument that one reason patent quality is stifling innovation is that the percentage of patent cases being heard by juries has increased from one in seven in the 1980's to seven in ten today, and in particular that many of those juries sit in the Eastern District of Texas (where "[a] patent is property, good Texans believe in property rights, and that pretty much settles it").  "Masterminds" behind these lawsuits hire lawyers who are "happy to switch from PI to IP," these attorneys being "local" counsel who "supply the neighborly face in the courtroom."  Ad hominem, indeed.

    Mr. Huber also believes that the fact that the Office is issuing 4,000 patents a week is another indication of poor quality.  An alternative explanation is that we live in the most technological age since the Industrial Revolution, that emerging economies in China and India are beginning to seek U.S. patent protection for their inventions, that the Office has hired almost 6,000 examiners in the past 5 years and that the Office spent about 4 years denying patents (the allowance rate shrank from about 60% to about 42%), and that those applicants who weathered that storm are now getting patents allowed; the "bubble" is much more likely to be the result of these forces than that the entire examining corps has decided to "allow, allow, allow" instead of performing their duties substantially as they always have.

    The end of Mr. Huber's piece invokes the specter of contingency fee cases, which are relatively rare in patent infringement litigation, and chides "members of the business community" who support patents and has even harsher words for "some conservative pundits [who] applaud the trolls, believing that this is how the market moves private property into the hands of the people who value it the most."  The piece ends predictably:

    The issue isn't whether intellectual property rights should be enforced, it's whether we have a reliable process for working out who really supplied the intellect.  We don't.  A system that issues and upholds junk patents will devalue intellectual property much faster than one that scrutinizes patents more carefully and enforces only the good ones.

    But the issue is precisely whether intellectual property rights should be enforced or ignored, because there will always be a sector of the business community (although recently it always seems to be the same sector) that will believe (and try to get others to believe) that they are the only repositories of "innovation" and that anyone (especially anyone without their economic resources) who asserts rights in their own inventions is a troll.  Once again, it ain't necessarily so.

  • By Brad Crawford

    EPO On April 13, 2011, the European Patent Office (EPO) reported that the total number of European patent applications is once again on the rise.  The EPO noted that EP filings hit 235,029 in 2010, which surpassed the 225,971 patent applications that were filed in 2008 and the 211,344 applications that were filed in 2009, and constituted the highest number of EP filings in the EPO's 34-year history.  As shown in the table below, the 235,029 filings in 2010 constituted increases of 4% relative to 2008 and 11% relative to 2009; in contrast, EP filings were down 6% in 2009 relative to 2008.

    Table 1
    A graphical representation of the above data can be viewed here.  A closer look at this data shows that U.S. applicants were responsible for the largest number of filings on a per country basis, with 60,588 applications filed in 2010.  Japan ranked second with a total of 41,917 filings, and Germany ranked third with 33,139 applications filed.  Somewhat disappointingly, filings by U.S. and German applicants, while up strongly from 2009, were still slightly below 2008 totals.  In contrast, Japanese applicants increased their filings in 2010 by 6% relative to 2008.  Applicants in the 38 member states of the EPC filed 92,553 applications in 2010, with applicanst in the EU-27 (i.e., the members of the European Union) accounting for 82,828 of these applications.  While U.S., German, EPC, and EU-27 filings were down slightly in 2010 relative to 2008, significant growth over the same time period was seen in China, with a 96% increase, and Korea, with a 20% increase.  Thus, the overall increase in filings at the EPO from 2008 to 2010 is largely attributable to an increase in filings from several Asian countries.

    As shown in the table below, the EPO also provided filing data with respect to technological field.

    Table 2
    The field of medical technology was responsible for the largest number of EP filings (10,479) in 2010, with computer technology (8,257) and electrical machinery/apparatus/energy (8,241) rounding out the top three technical fields.  When compared with 2008, 2009 filings were down in all fields except for medical technology and digital communication.  The news was better in 2010, as filings were up in all technological fields except for transport, which saw a 2.5% decrease relative to 2009 and a 14% decrease relative to 2008.  A comparison of filings in the various technology fields in 2010 and 2008 revealed some interesting trends.  The four worst performing fields were:  (1) telecommunications (filings down 21.6%), (2) transport (-14.0%), (3) computer technology (-10.2%), and (4) measurement (-9.7%).  In contrast, over the same time period the four technological fields with significant increases in the number of applications filed were:  (1) biotechnology (filings up 33.2%), (2) digital communication (25.0%), (3) pharmaceuticals (8.2%), and (4) medical technology (7.9%).

    Finally, the EPO provided data on applicants who filed the most applications at the EPO in 2010, all of which were electronics companies.  The top three spots went to Siemens, with 2,135 filings, Philips (1,765 applications), and BASF (1,707 applications).  A list of the top 50 filers in 2010 can be viewed here.  Biotechnology and pharmaceutical applicants making the top 50 included Bayer (#10, 1,123 filings), Hoffman-La Roche (#15, 811 filings), Johnson & Johnson (#20, 709 filings), Novartis (#27, 630 ffilings), DuPont (#29, 568 filings), sanofi-aventis (#33, 507 filings), and Abbott (#44, 393 filings).

  • By Donald Zuhn

    NVCA Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the first quarter of 2011.  The NVCA quarterly study, which the group conducts with PriceWaterhouseCoopers using data from Thomson Reuters, indicates that venture capitalists invested $5.9 billion in 736 deals during the first quarter, which constituted a 5% increase in dollars and a 11% drop in deals as compared with the fourth quarter of 2010 when $5.6 billion was invested in 827 deals.  While the 736 deals represented the lowest number of deals since the third quarter of 2009, the 5% increase in dollars marked the first time in four years that dollars invested rose between the fourth and first quarters.

    In the Life Sciences sector (biotechnology and medical devices), $1.4 billion was invested in 164 deals, for a 16% increase in dollars and a 9% drop in deals from the fourth quarter.  The biotech industry alone received $784 million via 85 deals, which marked a 6% increase in dollars and a 17% drop in deals as compared to the fourth quarter of 2010.  In terms of dollars invested, the biotechnology industry placed third among the sectors the NVCA report tracks.  However, the number of biotech deals was at its lowest point since the second quarter of 2003.  Of the seventeen sectors analyzed for the report, the NVCA noted that seven experienced double-digit increases in dollars invested in the first quarter.

    PricewaterhouseCoopers (PWC) Noting that fourteen companies received funding rounds of $50 million or more, which marked the largest number of such deals since the third quarter of 2001, Tracy Lefteroff, the global managing partner of the venture capital practice at PriceWaterhouseCoopers US, stated that "[t]his is a clear indicator that VCs are seeing innovative companies walk through their doors and that the entrepreneurial spirit of America is alive and well and thriving."  Stating that "[w]hat we are not seeing this quarter is just as critical as what we are seeing," NVCA president Mark Heesen pointed out that venture capital dollars were not flooding any particular sectors, and perhaps more importantly, that there was no "mass exodus from sectors, such as life sciences, where significant challenges lie."  Instead, Mr. Heesen explained that "[w]hat this deliberate and prudent pace of investment lacks in hype, it makes up for in sustainability, and we are very encouraged for the coming year."

    Thomson Reuters In a MoneyTree Report for 2010 issued earlier this year, the NVCA noted that $21.8 billion was invested in 3,277 deals in 2010, which constituted a 19% increase in dollars and a 12% increase in deals over 2009.  The rise in venture funding was the first increase since 2007.  The biotechnology industry, however, only saw modest gains in 2010, with dollars up 3% to $3.7 billion and deals up 8% to 460.  The biotech industry received the second highest level of funding in 2010, behind the software industry's $4.0 billion and 835 deals.

  • By Donald Zuhn

    Last week, the House Judiciary Committee, following in the footsteps of its Senate counterpart, reported a patent reform bill — in this case H.R. 1249 — out of committee and to the floor of the House for a possible vote (see "House Judiciary Committee Approves H.R. 1249").  The Committee's approval of the legislation followed the addition of thirteen amendments during a Thursday mark-up of the bill, the introduction earlier in the week of a Manager's Amendment for H.R. 1249, and the introduction of the House bill at the end of March.  Along the way, patent organizations and industry groups have lined up in support or opposition of the Committee's every move.  And so it was with the House Judiciary Committee's approval of H.R 1249.

    Biotechnology Industry Organization (BIO) In a statement released by the Biotechnology Industry Organization (BIO), the group noted that while it "has consistently praised House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a comprehensive patent reform bill similar to the bill adopted by the U.S. Senate earlier this month by a nearly unanimous vote," it would "have no choice but to oppose floor consideration of the bill . . . given the addition of the Goodlatte supplemental examination amendment, added to the bill during Committee consideration" (see "House Judiciary Committee Approves H.R. 1249").  BIO explained that "[t]he supplemental examination provision as passed by the Senate and originally included in the House bill would allow patent holders to seek a review of their issued patents at their own risk," but that "[t]he Goodlatte amendment undercuts this provision by creating disincentives for patent owners to use the new procedure by having the U.S. Patent and Trademark Office (PTO) act as quasi-investigative body."  Although BIO commended the Committee for approving a bill that "is a clear improvement over prior House versions of patent reform legislation," the organization noted its "objection to this bill being considered on the House floor" until such time as the supplemental examination issue is rectified.

    AIPLA The American Intellectual Property Law Association (AIPLA) issued a press release in which the group applauded the Committee's approval of H.R. 1249, adding that it "commends House Judiciary Committee Chairman Lamar Smith (R-Tex) for shepherding patent reform legislation another step closer to enactment."  The AIPLA noted that "members of the Committee gave serious consideration to a variety of amendments to the bill and concluded with an overwhelming, bi-partisan vote of 32-3 in support of the long-overdue improvements to the patent law."  While conceding that "more work is yet to be done," the AIPLA stated that "the Committee's effort represents encouraging progress."

    Innovation Alliance In a statement issued by the Innovation Alliance, the group (which represents innovators, patent owners, and stakeholders from a diverse range of industries) applauded the changes made during the House Judiciary Committee's mark-up of H.R. 1249, but "urge[d] further changes."  While the group expressed its appreciation for "the work of the Judiciary Committee in adopting several important amendments, including the Manager's Amendment, that [it] believe[s] improve the America Invents Act significantly while also defeating several very problematic amendments," the Innovation Alliance contended that "there are still important changes that should be made to ensure that [the legislation] fosters economic growth and job creation without favoring any business model or industry over another."  The group in particular pointed to provisions relating to business method patents, extended deadlines for inter partes reexamination, joinder, and prior user rights as being "harmful" and recommended that such provisions "should be removed" from the bill.  As the group has repeated a number of times in the past few weeks, it "continue[s] to believe the best course for policymakers is to focus on providing the U.S. Patent and Trademark Office with the funding and resources it needs to reduce its backlog."  However, the Innovation Alliance noted that it was "pleased with the progress" the House Judiciary Committee made on the bill last week and pledged to work with the Committee and members of the House "to arrive at a version of the America Invents Act that can secure our support."

    For additional information regarding this and other related topics, please see:

    • "House Judiciary Committee Approves H.R. 1249," April 14, 2011
    • "Reaction to Manager's Amendment to House Patent Reform Bill," April 13, 2011
    • "House Judiciary Chairman Releases Manager's Amendment to H.R. 1249," April 12, 2011
    • "Reaction to House Patent Reform Bill," March 31, 2011
    • "House Introduces Its Version of 'America Invents Act,'" March 30, 2011
    • "Patent Reform Discussion Moves to House," March 29, 2011
    • "The Disappearance of Deceptive Intent in S. 23," March 23, 2011
    • "'Reform' at the U.S. Patent and Trademark Office," March 22, 2011
    • "Few 'Reform' Provisions Remain in S. 23 Relating to the Judiciary," Marech 21, 2011
    • "Additional Opportunities for Pre- and Post-grant Review, and Brand New Patent Trial and Appeal Board in S. 23," March 17, 2011
    • "Post-grant Review Provisions of S. 23," March 16, 2011
    • "Inventor's Interests, If Not Rights, Limited by S. 23," March 15, 2011
    • "What Are the Provisions of the Proposed "First-Inventor-to-File" System in S. 23?" March 14, 2011
    • "Obama Administration Supports S. 23," March 9, 2011
    • "Reaction to Senate Passage of S. 23," March 8, 2011
    • "Senate Passes S. 23," March 8, 2011

  • IPLAC The Intellectual Property Law Association of Chicago (IPLAC) Biotech Committee and the John Marshall Law School Center for Intellectual Property Law will offer a panel discussion entitled:  "Gene Patents . . . Statutory Subject Matter?" on April 28, 2011 from 1:00 to 2:30 PM (CDT) at the John Marshall Law School in Chicago, IL.  The panel discussion will focus on the Association for Molecular Pathology v. U.S. Patent and Trademark Office case, which was argued before the Federal Circuit on April 4, 2011.  Panelists will include Dr. Hans Sauer, Associate General Counsel for Intellectual Property for the Biotechnology Industry Organization (BIO) and Adjunct Professor of Law at the Georgetown University Law Center; Joshua D. Sarnoff, Associate Professor of Law at the DePaul University College of Law; Patent Docs author Dr. Kevin E. Noonan, Partner with McDonnell Boehnen Hulbert & Berghoff LLP and Adjunct Professor at the DePaul University College of Law and The John Marshall Law School; and Kevin Collins, Professor of Law at the Washington University School of Law.

    Myriad Patent Docs readers may recall that Dr. Sauer and Prof. Sarnoff participated in a public radio discussion of the AMP v. USPTO case back in June 2009 (see "Gene Patenting Debate Continues").  Dr. Sauer was also of counsel on BIO's amicus brief in support of reversal  (see "BIO and AUTM File Joint Amicus Brief in AMP v. USPTO").  Prof. Sarnoff, meanwhile, authored an amicus brief on behalf of the American Medical Association et al. in support of plaintiffs-appellees and affirmance.  Dr. Noonan co-authored an amicus brief for the Intellectual Property Owners Association (IPO) (see "IPO Files Amicus Brief in AMP v. USPTO"), appeared on "60 Minutes" in April 2010 to discuss the AMP v. USPTO case (see "'60 Minutes' and 'Newshour' Take Different Approaches to Covering Gene Patenting Story"), and has written extensively on gene patenting and the AMP v. USPTO case in this space.  Prof. Collins has written and presented on diagnostic method claims (see "Patenting Information").

    ACLU The registration fee for the panel discussion is $10 (students), $20 (IPLAC members), or $30 (non-IPLAC members).  IPLAC is an Accredited CLE Provider, and it is anticipated that the program will be eligible for 1.5 hours of CLE credit.  In addition, Patent Docs will be providing lunch for attendees.  Those interested in registering for the panel discussion should contact Paul Reinfelds at PREI@Lundbeck.com or Donald Zuhn at zuhn@mbhb.com to reserve a spot.